User:Mr. Ibrahem/Enasidenib
 | |
| Clinical data | |
|---|---|
| Trade names | Idhifa |
| Other names | Enasidenib mesylate, AG-221 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617040 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Isocitrate dehydrogenase 2 inhibitor[1] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C19H17F6N7O |
| Molar mass | 473.383 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Enasidenib, sold under the brand name Idhifa, is a medication used to treat acute myeloid leukemia (AML) with mutations of the isocitrate dehydrogenase 2 (IDH2) gene.[1] It is used when other treatments have failed.[2] It is taken by mouth.[2]
Common side effects include nausea, diarrhea, high bilirubin, and lose of appetite.[2] Other side effects may include differentiation syndrome, tumor lysis syndrome, lung problems, infertility, and kidney problems.[1] Use during pregnancy may harm the baby.[2] It works by blocking the action of mutated IDH2.[3]
Enasidenib was approved for medical use in the United States in 2017.[1] It was denied approval in Europe in 2019 due to insufficient evidence of benefit.[3] In the United States a month of treatment costs about 29,500 USD as of 2021.[4]
References[edit]
- ^ a b c d e "Enasidenib Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 15 December 2021.
- ^ a b c d e f "DailyMed - IDHIFA- enasidenib mesylate tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 23 March 2021. Retrieved 15 December 2021.
- ^ a b "Idhifa: Withdrawal of the marketing authorisation application". Archived from the original on 20 November 2021. Retrieved 15 December 2021.
- ^ "Idhifa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 April 2021. Retrieved 15 December 2021.